LYKOS THERAPEUTICS — Lobbying Disclosure | Poliscope

LYKOS THERAPEUTICS

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$1.1M

Filings

Firms Hired

Active Period

2022–2025

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2025	$180,000	4	2
2024	$510,000	11	2
2023	$410,000	9	2
2022	—	2	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
LYKOS THERAPEUTICS	$1,100,000	12
FORBES-TATE	—	14

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	23
SENATE	22
White House Office	2
Veterans Affairs, Dept of (VA)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Veterans	Veterans	25
Health Issues	Health Issues	25
Budget/Appropriations	Budget/Appropriations	22
Defense	Defense	22
Pharmacy	Pharmacy	1
Science/Technology	Science/Technology	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2483119th Congress

SUPPORT for Patients and Communities Reauthorization Act of 2025

2025 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical distribution (SUPPORT for Patients and Communities Reauthorization Act of 2025, H.R. 2483 / S. 2121).

Client expense: $90,000 · Firm income: —

Matched citations: H.R. 2483

H.R. 3944119th Congress

Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026

2025 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); issues related to therapeutics and implementation research and development (Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, H.R. 3944 / no Senate bill number).

Client expense: $90,000 · Firm income: —

Matched citations: H.R. 3944

H.R. 3944119th Congress

Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026

2025 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); issues related to therapeutics and implementation research and development (Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, H.R. 3944 / no Senate bill number).

Client expense: $90,000 · Firm income: —

Matched citations: H.R. 3944

H.R. 3944119th Congress

Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026

2025 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); issues related to therapeutics and implementation research and development (Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, H.R. 3944 / no Senate bill number).

Client expense: $90,000 · Firm income: —

Matched citations: H.R. 3944

Show 21 more cited filings

S. 2121119th Congress

SUPPORT for Patients and Communities Reauthorization Act of 2025

2025 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical distribution (SUPPORT for Patients and Communities Reauthorization Act of 2025, H.R. 2483 / S. 2121).

Client expense: $90,000 · Firm income: —

Matched citations: S. 2121

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · fourth_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development).

Client expense: $110,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · fourth_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development).

Client expense: $110,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · fourth_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development).

Client expense: $110,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4531118th Congress

Support for Patients and Communities Reauthorization Act

2024 · fourth_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 4531 / S. 3393, Support for Patients and Communities Reauthorization Act (provisions related to pharmaceutical distribution).

Client expense: $110,000 · Firm income: —

Matched citations: H.R. 4531

S. 2127118th Congress

Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024

2024 · fourth_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development).

Client expense: $110,000 · Firm income: —

Matched citations: S. 2127

S. 2127118th Congress

Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024

2024 · fourth_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development).

Client expense: $110,000 · Firm income: —

Matched citations: S. 2127

S. 2127118th Congress

Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024

2024 · fourth_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development).

Client expense: $110,000 · Firm income: —

Matched citations: S. 2127

S. 3393118th Congress

SUPPORT for Patients and Communities Reauthorization Act

2024 · fourth_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 4531 / S. 3393, Support for Patients and Communities Reauthorization Act (provisions related to pharmaceutical distribution).

Client expense: $110,000 · Firm income: —

Matched citations: S. 3393

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · third_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $160,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · third_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $160,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · third_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $160,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4531118th Congress

Support for Patients and Communities Reauthorization Act

2024 · third_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 4531 / S. 3393, Support for Patients and Communities Reauthorization Act (issues related to pharmaceutical distribution).

Client expense: $160,000 · Firm income: —

Matched citations: H.R. 4531

S. 2127118th Congress

Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024

2024 · third_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $160,000 · Firm income: —

Matched citations: S. 2127

S. 2127118th Congress

Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024

2024 · third_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $160,000 · Firm income: —

Matched citations: S. 2127

S. 2127118th Congress

Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024

2024 · third_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $160,000 · Firm income: —

Matched citations: S. 2127

S. 3393118th Congress

SUPPORT for Patients and Communities Reauthorization Act

2024 · third_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 4531 / S. 3393, Support for Patients and Communities Reauthorization Act (issues related to pharmaceutical distribution).

Client expense: $160,000 · Firm income: —

Matched citations: S. 3393

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $120,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $120,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD (no bill); H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (issues related to therapeutics research and development).

Client expense: $120,000 · Firm income: —

Matched citations: H.R. 4366

H.R. 4531118th Congress

Support for Patients and Communities Reauthorization Act

2024 · second_quarter · Firm: LYKOS THERAPEUTICS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 4531 / S. 3393, Support for Patients and Communities Reauthorization Act (issues related to pharmaceutical distribution).

Client expense: $120,000 · Firm income: —

Matched citations: H.R. 4531

Source: Senate LDA